Get the scoop on pre-market movers and shakers in the US stock market.

Why Did Citius Pharmaceuticals Stock Plunge 29.93%?

Before the BellTuesday, Jun 10, 2025 7:13 am ET

1min read

On June 10, 2025, Citius experienced a significant drop of 29.93% in pre-market trading, marking a notable decline in its stock performance.

Citius Pharmaceuticals has seen substantial volatility in its stock price recently. On Monday, the company's shares soared by 73.92% to $1.48 during the session, with shareholders witnessing a 21.75% increase in the stock price. This volatility was also evident in the intraday session, where Citius Pharmaceuticals' shares rose by 121.5% to $1.89, reflecting a significant market cap of $19.3 million.

Analysts at H.C. Wainwright revised their price target for Citius Pharmaceuticals, lowering it from $100 to $4 while maintaining a Buy rating. This adjustment comes amidst the company's recent announcements, including a distribution services agreement that has contributed to the stock's upward momentum.

Citius Pharmaceuticals' stock performance has been influenced by its strategic moves and market dynamics. The company's entry into a distribution services agreement has been a key driver, leading to a surge in its stock price. This agreement is part of Citius Pharmaceuticals' broader strategy to develop and commercialize first-in-class critical care products, positioning the company for potential growth in the biopharmaceutical sector.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.